GGrantIndex
← Leaderboards

Randall F Holcombe

University Of California Irvine

$5,463,874
Attributed
$7,530,583
Total exposure
10
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $4.4M · FY200520
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20

Funding mix

By agency

NIH$18,357,157 · 11

By mechanism

P30$13,110,642 · 4
UG1$2,649,804 · 1
K24$1,378,909 · 1
R21$849,111 · 2
R03$303,409 · 1
M01$65,282 · 2

Top collaborators

Others in their field

Top investigators on “Clinical Research

Research focus

Clinical ResearchMalignant NeoplasmsCancer PreventionUniversitiesCancer CenterClinical TrialsHawaiiProgramsFundingCharacteristicsResearch PersonnelCancer Center Support GrantMissionCancer ControlPatient CareBaseCancer BurdenAreaFacultyDesignEvaluationEthnic DiversityResource SharingCollaborations

Grant awards (38)

University of Hawaii Cancer Center CCSG$2,156,000
P30 · FY2020 · CA · contact PI
The Hawaii Minority/Underserved NCORP$1,276,438
UG1 · FY2020 · CA
Leadership, Planning and Evaluation$391,788
P30 · FY2020 · CA · contact PI
Developmental Funds$347,616
P30 · FY2020 · CA · contact PI
University of Hawaii Cancer Center CCSG$115,000
P30 · FY2020 · CA · contact PI
Community Outreach and Engagement$53,416
P30 · FY2020 · CA · contact PI
University of Hawaii Cancer Center CCSG$2,141,479
P30 · FY2019 · CA · contact PI
The Hawaii Minority/Underserved NCORP$1,373,366
UG1 · FY2019 · CA
Leadership, Planning and Evaluation$389,152
P30 · FY2019 · CA · contact PI
Developmental Funds$345,276
P30 · FY2019 · CA · contact PI
University of Hawaii Cancer Center CCSG$115,000
P30 · FY2019 · CA · contact PI
Community Outreach and Engagement$53,058
P30 · FY2019 · CA · contact PI
University of Hawaii Cancer Center CCSG$1,913,800
P30 · FY2018 · CA · contact PI
Leadership, Planning and Evaluation$347,778
P30 · FY2018 · CA · contact PI
Developmental Funds$308,567
P30 · FY2018 · CA · contact PI
Community Outreach and Engagement$47,417
P30 · FY2018 · CA · contact PI
University of Hawaii Cancer Center CCSG$2,156,000
P30 · FY2017 · CA · contact PI
University of Hawaii Cancer Center CCSG$1,913,800
P30 · FY2016 · CA · contact PI
University of Hawaii Cancer Center CCSG$200,000
P30 · FY2016 · CA · contact PI
University of Hawaii Cancer Center CCSG$115,495
P30 · FY2016 · CA · contact PI
Neoadjuvant photodynamic immunomodulation for colon cancer$302,100
R21 · FY2011 · CA
Neoadjuvant photodynamic immunomodulation for colon cancer$298,246
R21 · FY2010 · CA
Patient-oriented Research: Colon CA & Cancer Immunology$91,205
K24 · FY2010 · CA · contact PI
Patient-oriented Research: Colon CA & Cancer Immunology$58,375
K24 · FY2010 · CA · contact PI
PHASE I BIOMARKER STUDY OF DIETARY GRAPE-DERIVED LOW DOSE RESVERATROL FOR COLON$172
M01 · FY2010 · RR · contact PI
Patient-oriented Research: Colon CA & Cancer Immunology$149,580
K24 · FY2009 · CA · contact PI
PHASE I BIOMARKER STUDY OF DIETARY GRAPE-DERIVED LOW DOSE RESVERATROL FOR COLON$65,110
M01 · FY2009 · RR · contact PI
Patient-oriented Research: Colon CA & Cancer Immunology$149,580
K24 · FY2008 · CA · contact PI
Patient-oriented Research: Colon CA & Cancer Immunology$148,562
K24 · FY2007 · CA · contact PI
A Phase 1 Study of CCI-779 in Combination with Imatnib *$248,765
R21 · FY2006 · CA · contact PI
Patient-oriented Research: Colon CA & Cancer Immunology$145,808
K24 · FY2006 · CA · contact PI
Wnt Signaling in IBD-Related Colon Cancer$151,909
R03 · FY2005 · DK
Patient oriented Research--Colon CA &Cancer Immunology$127,023
K24 · FY2005 · CA
Wnt Signaling in IBD-Related Colon Cancer$151,500
R03 · FY2004 · DK
Patient oriented Research--Colon CA &Cancer Immunology$126,987
K24 · FY2004 · CA
Patient oriented Research--Colon CA &Cancer Immunology$126,953
K24 · FY2003 · CA
Patient oriented Research--Colon CA &Cancer Immunology$126,921
K24 · FY2002 · CA
Patient oriented Research--Colon CA &Cancer Immunology$127,915
K24 · FY2001 · CA